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Abstract
Background
This study reports the findings of the first large-scale Phase III investigator-driven clinical
trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP)
calcium channel blocker, nilvadipine. Nilvadipine, licensed to treat hypertension, reduces
amyloid production, increases regional cerebral blood flow, and has demonstrated anti-
inflammatory and anti-tau activity in preclinical studies, properties that could have disease-
modifying effects for Alzheimer disease. We aimed to determine if nilvadipine was effective
in slowing cognitive decline in subjects with mild to moderate Alzheimer disease.
Methods and findings
NILVAD was an 18-month, randomised, placebo-controlled, double-blind trial that rando-
mised participants between 15 May 2013 and 13 April 2015. The study was conducted at 23
academic centres in nine European countries. Of 577 participants screened, 511 were eligi-
ble and were randomised (258 to placebo, 253 to nilvadipine). Participants took a trial treat-
ment capsule once a day after breakfast for 78 weeks. Participants were aged >50 years,
meeting National Institute of Neurological and Communicative Disorders and Stroke/Alzhei-
mer’s disease Criteria (NINCDS-ADRDA) for diagnosis of probable Alzheimer disease, with
a Standardised Mini-Mental State Examination (SMMSE) score of12 and <27. Partici-
pants were randomly assigned to 8 mg sustained-release nilvadipine or matched placebo.
The a priori defined primary outcome was progression on the Alzheimer’s Disease Assess-
ment Scale Cognitive Subscale-12 (ADAS-Cog 12) in the modified intention-to-treat (mITT)
population (n = 498), with the Clinical Dementia Rating Scale sum of boxes (CDR-sb) as a
gated co-primary outcome, eligible to be promoted to primary end point conditional on a sig-
nificant effect on the ADAS-Cog 12. The analysis set had a mean age of 73 years and was
62% female. Baseline demographic and Alzheimer disease–specific characteristics were
similar between treatment groups, with reported mean of 1.7 years since diagnosis and
mean SMMSE of 20.4. The prespecified primary analyses failed to show any treatment ben-
efit for nilvadipine on the co-primary outcome (p = 0.465). Decline from baseline in ADAS-
Cog 12 on placebo was 0.79 (95% CI, −0.07–1.64) at 13 weeks, 6.41 (5.33–7.49) at 52
weeks, and 9.63 (8.33–10.93) at 78 weeks and on nilvadipine was 0.88 (0.02–1.74) at 13
weeks, 5.75 (4.66–6.85) at 52 weeks, and 9.41 (8.09–10.73) at 78 weeks. Exploratory anal-
yses of the planned secondary outcomes showed no substantial effects, including on the
CDR-sb or the Disability Assessment for Dementia. Nilvadipine appeared to be safe and
well tolerated. Mortality was similar between groups (3 on nilvadipine, 4 on placebo); higher
counts of adverse events (AEs) on nilvadipine (1,129 versus 1,030), and serious adverse
events (SAEs; 146 versus 101), were observed. There were 14 withdrawals because of
AEs. Major limitations of this study were that subjects had established dementia and the
likelihood that non-Alzheimer subjects were included because of the lack of biomarker con-
firmation of the presence of brain amyloid.
Conclusions
The results do not suggest benefit of nilvadipine as a treatment in a population spanning
mild to moderate Alzheimer disease.
Nilvadipine and Alzheimer disease
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Author summary
Why was this study done?
• There are few licensed drug treatments for Alzheimer disease and none are effective in
slowing the rate of disease progression.
• Nilvadipine is a licensed blood pressure medication and has been shown to lower brain
amyloid and improve memory function in animal models of Alzheimer disease.
• If nilvadipine were shown to be effective in slowing the rate of progression of Alzheimer
disease, because it is already licensed and available to treat high blood pressure, it would
be possible to introduce the drug for use in Alzheimer disease relatively quickly.
What did the researchers do and find?
• We carried out an investigator-led clinical trial funded by the European Union across
23 academic university sites and involving 511 patients with mild- and moderate-stage
Alzheimer disease, as diagnosed by a clinician.
• We tested whether a single dose of nilvadipine, compared with placebo, was safe and
slowed the progression of Alzheimer disease over a period of 18 months.
• We found that nilvadipine appeared safe and was well tolerated but did not slow decline
in cognition or function in this group of mild- and moderate-stage Alzheimer disease
patients.
What do these findings mean?
• Nilvadipine does not appear to be effective as a treatment for people with mild- or mod-
erate-stage Alzheimer disease.
• We cannot rule out that this medication may help at an earlier stage of the disease pro-
cess, before the person experiences loss of function.
Introduction
Observational studies have suggested a benefit of certain blood pressure medications on reduc-
ing the risk of developing dementia [1]. Particular antihypertensive agents have also been
shown to decrease Alzheimer disease pathology in the brains of people with hypertension,
independently of blood pressure control, suggesting a direct effect of these medications against
the biological processes underpinning Alzheimer disease [2,3]. One antihypertensive, for
which there is clinical and scientific rationale for disease-modifying efficacy in Alzheimer
Nilvadipine and Alzheimer disease
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disease, is nilvadipine. Nilvadipine is a dihydropyridine (DHP) calcium channel blocker and is
licensed in a number of countries to treat patients with hypertension. Nilvadipine is reported
to have a number of neuroprotective mechanisms of action other than direct calcium channel
blockade and maintenance of intracellular calcium homeostasis, including lowering Amyloid
beta 40 and 42 amino acid peptides (Aβ40 and Aβ42) production in vitro and in vivo in trans-
genic mouse models of Alzheimer disease, and enhancing Aβ clearance across the blood–brain
barrier in in vivo mouse models [4,5]. However, many other DHPs do not share these proper-
ties and some may actually increase Aβ40 and Aβ42 production in vitro [4], demonstrating
that amyloid lowering is not a class effect of DHPs. In addition to effects on Aβ production
and clearance, nilvadipine specifically has also shown efficacy against a broad range of other
putative Alzheimer disease pathological mechanisms, including tau-phosphorylation, reduced
cerebral blood flow, and neuroinflammation [6–9].
In clinical studies, nilvadipine stabilised cognitive decline and reduced conversion to Alz-
heimer disease in a small study of patients with hypertension and mild cognitive impairment
[10]. Another 6-week open label study demonstrated that nilvadipine was safe and well toler-
ated in patients with Alzheimer disease and did not reduce blood pressure in nonhypertensive
patients with Alzheimer disease, but appropriately lowered blood pressure in hypertensive
cases [11].
These studies are complemented by a number of epidemiological and interventional studies
involving different calcium channel blockers that have reported on the potential benefit of this
drug class in the prevention of Alzheimer disease. In the treatment of Systolic Hypertension in
Europe (Syst-Eur) trial, which involved over 2,400 older participants with systolic hyperten-
sion treated with the DHP calcium channel blocker, nitrendipine, there was a reported 55%
reduction in the incidence of Alzheimer disease [12,13]. The Baltimore Longitudinal Study of
Aging found a nonsignificant apparent benefit towards reduced relative risk of Alzheimer dis-
ease in patients treated with DHP calcium channel blockers, with no lowered risk observed in
the non-DHP calcium channel blocker treatment group [14].
To our knowledge, there has been no definitive intervention study with a calcium channel
blocker to test for an effect on slowing the rate of cognitive decline in patients with Alzheimer
disease.
Given the previous preclinical and clinical data suggesting the potential efficacy for nilvadi-
pine and related compounds against Alzheimer disease, the objective of this 78-week rando-
mised, placebo-controlled study was to determine whether treatment with nilvadipine
sustained-release 8 mg, once a day, was effective and safe in slowing the rate of cognitive
decline in patients with mild to moderate Alzheimer disease.
Methods
Study design
This 18-month Phase III, randomised, placebo-controlled, double-blind, parallel-group study
was carried out at 23 academic centres in nine European countries: Ireland (two sites), United
Kingdom (one site), Italy (four sites), the Netherlands (three sites), France (seven sites), Greece
(three sites), Sweden (one site), Germany (one site), and Hungary (one site) (S1 Table). The
trial project office was based at St. James’s Hospital, Dublin, Ireland, which was also the spon-
sor. The trial coordinating institution was Trinity College, University of Dublin, and the trial
was funded by the European Commission, under a Framework 7 Programme Health Theme
collaborative project grant. The trial database, randomisation, and allocation system were
maintained by the Clinical Trials Unit at King’s College London, and the statistical analysis
was conducted at the University College Dublin Centre for Support and Training in Analysis
Nilvadipine and Alzheimer disease
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and Research (UCD CSTAR). As part of the overall governance of the trial, there was a Scien-
tific Advisory Board, an independent Ethics Advisory Board, and an independent Data Safety
Monitoring Board. Approval of the study protocol and all related documents was obtained
from the appropriate National Competent Authorities, Independent Ethics Committees, and
Institutional Review Boards for all study sites. Additional information is provided below and
in supplementary files S1 Text (study design and treatment), S2 Text (detailed statistical meth-
ods), and S3 Text (trial-associated boards).
Participants
A detailed list of inclusion and exclusion criteria is provided in the published protocol [15].
Briefly, participants were aged>50 years, meeting National Institute of Neurological and
Communicative Disorders and Stroke/Alzheimer’s disease Criteria (NINCDS-ADRDA) for
diagnosis of probable Alzheimer disease [16], with a Standardised Mini-Mental State Examina-
tion (SMMSE) [17] score of12 and <27, and having a caregiver available to complete rele-
vant assessment instruments. If on a cholinesterase inhibitor or memantine, the dose had to be
stable for>12 weeks. People with dementia because of other causes or with known sensitivity
to calcium channel blockers were excluded.
All participants provided written informed consent before enrolling in the study. The con-
sent form was amended as required in each country to comply with local ethics requirements.
All caregivers also provided consent for involvement.
Randomisation and masking
Participants were randomly assigned to nilvadipine sustained-release 8 mg or placebo using
block randomisation with randomly varying block sizes, stratified by site, using an online sys-
tem integrated with stock control across sites. Participants, caregivers, and assessors were
blinded to treatment assignment.
Procedures
Participants took a trial treatment capsule once a day after breakfast for 78 weeks and returned
their used treatment boxes at subsequent dispensing visits, when the number of returned cap-
sules was recorded. Participants were assessed at 6, 13, 26, 39, 52, 65, and 78 weeks after com-
mencing treatment. Participants were followed up 4 weeks after the final, week 78 visit.
Outcomes
The co-primary outcome measures were the change from baseline in the 12-item Alzheimer
Disease Assessment Scale–Cognitive Subscale (ADAS-Cog 12) [18] and the Clinical Dementia
Rating scale sum of boxes (CDR-sb) [19]. The key secondary outcome measure was the Dis-
ability Assessment for Dementia (DAD) [20], as maintenance of functional abilities is consid-
ered a crucial benefit of any potential treatment. Data on all primary and secondary outcome
measures were collected at baseline and at 13, 52, and 78 weeks. Safety was assessed through
the collection of data on adverse events (AEs), blood pressure, and laboratory tests.
Statistical analysis
The sample size of 250 patients in each group was calculated to allow detection of a 50% reduc-
tion in cognitive decline in the nilvadipine group over the 78 weeks of follow-up [15]. This
resulted in 90% power to detect a 3.5-point group difference in the decline in ADAS-Cog 12
Nilvadipine and Alzheimer disease
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(SD = 10), and 81% power to also detect a significant effect on the CDR-sb as a gated co-pri-
mary end point. The sample size calculation included allowance for 30% loss to follow-up.
The primary and secondary efficacy analyses were conducted in a modified intention-to-
treat (mITT) population, including all participants randomised who had both a baseline
assessment and at least one later assessment. The safety set included all patients who took at
least one dose of the trial treatment.
A secondary per-protocol analysis was carried out using only those patients compliant with
medication (defined as taking >80% of doses) and with all assessments on schedule.
The primary and secondary end point analyses consisted of linear mixed-effects models,
with country as a random effect and correlated residuals over time. Findings hinged on a p-
value less than 0.05 for a (Visit × Arm) interaction test using change scores from baseline and
adjusting for the baseline score. We adopted a gated approach to control the false positive rate
over multiple end points. The ordered outcomes were as follows: change from baseline of
ADAS-Cog 12 (analysed in discrete time); followed by the change in CDR-sb; then, in order,
ADAS-Cog 12 and CDR-sb were to be tested for a linear improvement over continuous time.
The key secondary outcome of DAD was next on the list, followed by the other secondary out-
comes. In the case of a nonsignificant result, any further analyses are purely exploratory, with
no further tests of a null hypothesis. Full technical details and description of the gated
approach and statistical models are given in the S1 Text file.
Responder analyses were conducted on a dichotomised change score from baseline to week
78 using logistic regression, with no imputation for missing values. Preplanned subgroup anal-
yses included examination of a difference in nilvadipine effect size between mild and moderate
Alzheimer disease (20 versus <20 on baseline SMMSE, respectively), between males and
females, and between Apolipoprotein E gene (APOE) ε4 allele carriers and noncarriers. The
latter analysis was limited to the patient subgroup that participated in the blood biomarker
study [21]. Subgroup differences in efficacy were examined by a three-way interaction of the
subgroup with visit and treatment arms.
Baseline and safety end points were tested by standard tests for proportions (Pearson chi-
squared test) or rates (Poisson count model), with no corrections applied for multiple testing.
An independent Data Safety Monitoring Board, blind to group assignment, reviewed safety
data throughout the trial.
This trial adhered to the Declaration of Helsinki and International Conference on Harmo-
nisation Good Clinical Practice (ICH GCP) guidelines and was conducted in compliance with
the protocol, data protection regulations, and all other regulatory requirements, as
appropriate.
Results
Participants
Between 15 May 2013 and 13 April 2015, 511 eligible participants were randomised; the last
outcomes visit was in November 2016. Of the 511 randomised, 498 had at least one post-base-
line ADAS-Cog 12 assessment and comprised the mITT population (Fig 1), with 247 on nilva-
dipine and 251 on placebo. The proportion of ADAS-Cog 12 assessments completed was high,
allowing us to exceed our sample size target (see Fig 1). Trial medication was interrupted by
103 patients during the course of the study (55 nilvadipine, 48 placebo), of whom 4 resumed
medication; mean treatment compliance was 88% (capsules taken over days in study), and
80.4% of patients were compliant with assigned medication at a threshold of 80% of capsules
taken, balanced between arms.
Nilvadipine and Alzheimer disease
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Baseline demographic and Alzheimer disease–specific characteristics were similar between
treatment groups (Table 1, Table 2). There were no significant differences at baseline or end of
trial in the prescribing of Alzheimer disease medications (acetylcholinesterase inhibitors and/
or memantine) or non-Alzheimer disease concomitant medications (Table 1). Vascular risk
factors, notably hypertension, hypercholesterolemia, and kidney disease, were also similar,
with the exception of diabetes, which was more common in the nilvadipine group (Table 1).
Comorbid medical conditions at baseline were substantially more prevalent in the nilvadipine
group than in the placebo group, and predominantly in the endocrine class, which included
diabetes (Table 1). APOE genotype was available from 161 participants in the nilvadipine
group and 167 in the placebo group.
Efficacy end points
No treatment effect was observed at a statistically significant level for the first primary outcome
analysis (p = 0.465). The nilvadipine difference from placebo, in change from baseline in the
ADAS-Cog 12 score, was −0.22 (95% CI, −2.01–1.57) (Table 3). Similarly, nilvadipine did not
show any clinically meaningful effects on CDR-sb and DAD (Table 3, Fig 2).
Per-protocol analyses showed identical patterns to the primary analysis. The prespecified
responder analysis showed no effects of nilvadipine on the proportion of patients maintaining
cognition or function as measured by the ADAS-Cog 12: odds ratio 1.09 (95% CI, 0.65–1.84),
the CDR-sb: odds ratio 1.74 (95% CI, 0.99–3.06), or the DAD: odds ratio 0.90 (95% CI, 0.54–
1.51).
The predefined subgroup analyses were inspected to identify group differences (S2 Table,
S3 Table, S4 Table); we note that no hypothesis tests were performed for these exploratory
analyses. Comparing those with mild to those with moderate Alzheimer disease, there was less
decline in the mild group on nilvadipine compared to placebo. However, a greater decline was
seen in the moderate group treated with nilvadipine. For gender, males showed less decline
than females on nilvadipine compared to placebo. Furthermore, APOE ε4 allele carriers
showed less decline than noncarriers on nilvadipine (S2 Table, S3 Table, S4 Table).
Safety
Participants who received at least one dose of the study drug comprised the safety population
(n = 509). Despite a higher total number of AEs or serious adverse events (SAEs) in the nilvadi-
pine group (Table 4) the number of patients with at least one AE or SAE were substantially
similar. The median change in systolic blood pressure from baseline to week 78 was −5 mmHg
and the number of falls, complaints of dizziness, or syncope were very similar between groups
(Table 4). The number of deaths was 10 (7participants died during the study duration and a
further 3 during the longer-term follow-up of SAEs). No deaths were judged by the investiga-
tors to be related to treatment. Emergent clinically significant blood test results on nilvadipine
and placebo from baseline to week 78 were too rare to draw conclusions but were not elevated
in the nilvadipine group. Between-group differences were observed on aggregated significant
and nonclinically significant abnormal blood markers; these reflected more elevated results on
placebo at trial end for creatinine (9%–13%) and calcium (7%–11%), or fewer elevated results
on nilvadipine for mean corpuscular volume (MCV) results (10%–7%) (S5 Table). A
Fig 1. Flowchart of the NILVAD study according to the CONSORT guideline. ADAS, Alzheimer’s Disease Assessment Scale-
Cognitive Subscale 12 item; BP, blood pressure; CDR, Clinical Dementia Rating Scale sum of boxes; DAD, Disability Assessment
for Dementia; ECG, electrocardiogram; IMP, investigational medicinal product; NILVAD, Nilvadipine in Alzheimer disease;
SMMSE, Standardised Mini-Mental State Examination.
https://doi.org/10.1371/journal.pmed.1002660.g001
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comparison of the Medical Dictionary for Regulatory Activities (MedDRA)-coded AEs (S6
Table) showed small differences (<6%) between groups for the following events: fall (worse on
placebo), cough, cellulitis, peripheral edema, insomnia, and hypotension.
Table 1. Characteristics of the modified intention-to-treat sample.
Characteristics Nilvadipine
(N = 247)
Placebo
(N = 251)
Demographics and anthropometrics
Sex N (%) Female 161 (65%) 147 (59%)
Baseline age (years) mean (SD) 73.1 (8.66) 72.8 (7.84)
Ethnicity N (%) White 241 (98%) 244 (97%)
Asian 1 (0.4%) 2 (0.8%)
Black 1 (0.4%) 4 (1.6%)
Other 4 (1.6%) 1 (0.4%)
Baseline BMI mean (SD) 25.3 (3.92) 25.8 (4.45)
Baseline blood pressure mean (SD) SBP/DBP 138 (14) / 77 (9) 137 (14) / 77 (9)
Week 13 blood pressure mean (SD) SBP/DBP 131 (15) / 73 (9) 137 (16) / 76 (9)
Week 52 blood pressure mean (SD) SBP/DBP 131 (15) / 74 (9) 135 (14) / 76 (9)
Week 78 blood pressure mean (SD) SBP/DBP 132 (16) / 74 (10) 135 (16) / 75 (9)
Baseline vascular risk factors
Diabetes 28 (12%) 12 (5%)
Kidney disease 3 (1%) 5 (2%)
Hypercholesterolemia 82 (34%) 83 (33%)
Hypertension 82 (34%) 87 (35%)
Baseline blood pressure (median SBP / DBP) 140 / 77 138 / 77
Week 78 blood pressure (median SBP / DBP) 130 / 74 135 / 74
Baseline medical status
Patients on AD concomitant medications 173 (69%) on 1; 65 (26%) on 2+ 170 (66%) on 1; 75 (29%) on 2+
Patients on non-AD concomitant medications 221 (88%) 219 (85%)
Comorbid medical conditions (per patient) mean (SD) 2.84 (2.09) 2.43 (1.87)
Data are mean (standard deviation), median (IQR: first and third quartiles), n (%), or n/N (%).
Abbreviations: AD, Alzheimer disease; BMI, body mass index; DBP, diastolic blood pressure; IQR, interquartile range; SBP, systolic blood pressure.
https://doi.org/10.1371/journal.pmed.1002660.t001
Table 2. Baseline Alzheimer disease characteristics.
Characteristics Sample statistics Nilvadipine
(N = 247)
Placebo
(N = 251)
Years since diagnosis mean (SD) 1.73 (1.66) 1.70 (1.78)
Years since symptom onset mean (SD) 4.31 (2.56) 4.28 (2.72)
APOE ε4 carrier n/N (%) 94/161 (58%) 100/167 (60%)
SMMSE mean (SD) 20.3 (3.76) 20.5 (3.89)
SMMSE < 20 N (%) 93 (38%) 94 (37%)
Baseline ADAS-Cog 12 mean (SD) 34.4 (10.5) 34.5 (10.8)
Baseline CDR-sb (N = 249 + 251) mean (SD) 5.34 (2.76) 5.17 (2.73)
Baseline DAD (N = 249 + 251) mean (SD) 29.7 (8.0) 30.4 (8.1)
Data are mean (standard deviation), n (%), or n/N (%).
Abbreviations: ε4, epsilon 4 allele; ADAS-Cog 12, Alzheimer Disease Assessment Scale–Cognitive Subscale (12 item); APOE, Apolipoprotein E gene; CDR-sb, Clinical
Dementia Rating sum of boxes; DAD, Disability Assessment for Dementia; SMMSE, Standardised Mini-Mental State Examination.
https://doi.org/10.1371/journal.pmed.1002660.t002
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Discussion
To our knowledge, this is the first definitive intervention study of nilvadipine, a DHP calcium
channel blocker with demonstrated Aβ-lowering properties in animal studies, for the treat-
ment of Alzheimer disease. The results of this study indicated no benefit of nilvadipine as a
treatment in a population spanning mild to moderate Alzheimer disease. There were no obvi-
ous methodological limitations that could have contributed to these negative findings for the
primary and secondary outcomes in the overall treatment population. Recruitment was to tar-
get, the dropout and missing data rates were low. The rate of decline in the placebo group on
the ADAS-Cog 12 was consistent with previous Phase III clinical trials involving mild to mod-
erate Alzheimer disease participants. Treatment and placebo arms were well balanced,
although there were more patients with abnormal glucose levels and with diabetes in the nilva-
dipine group at baseline. The higher frequency of diabetes in the nilvadipine group is unlikely
to have had a bearing on the overall negative finding, as the effect of diabetes on cognitive
decline in established Alzheimer disease is unclear [22]. Furthermore, data from a sub-study
confirm that there was no significant imbalance between the nilvadipine and the placebo
Table 3. Efficacy analyses for primary outcomes (ADAS-Cog 12 and CDR-sb), and the key secondary outcome (DAD).
Outcomes Week 0 Week 13 Week 52 Week 78 p-value
ADAS-Cog 12Ɨ Nilvadipine Mean ± SD 34.4 ± 10.5 35.2 ± 11.3 39.4 ± 13.1 41.9 ± 14.6
Δ (95% CI) 0.88 (0.02–1.74) 5.75 (4.66–6.85) 9.41 (8.09–10.73)
Placebo Mean ± SD 34.5 ± 10.8 35.3 ± 11.6 40.3 ± 13.9 41.9 ± 14.5
Δ (95% CI) 0.79 (−0.07–1.64) 6.41 (5.33–7.49) 9.63 (8.33–10.93)
Group difference 0.09 (−0.96–1.15) −0.65 (−2.10–0.80) −0.22 (−2.01–1.57) 0.465
CDR-sbǂ Nilvadipine Mean ± SD 5.34 ± 2.76 5.87 ± 2.96 7.29 ± 3.69 8.72 ± 4.60
Δ (95% CI) 0.54 (0.35–0.72) 2.02 (1.69–2.34) 3.49 (3.07–3.90)
Placebo Mean ± SD 5.17 ± 2.73 5.71 ± 3.17 7.22 ± 4.02 8.38 ± 4.45
Δ (95% CI) 0.51 (0.33–0.70) 2.19 (1.87–2.50) 3.52 (3.11–3.94)
Group difference 0.02 (−0.25–0.29) −0.17 (−0.62–0.28) −0.04 (−0.62–0.55) N/A
DAD§ Nilvadipine Mean ± SD 29.7 ± 8.0 28.4 ± 8.2 24.3 ± 10.2 21.1 ± 11.5
Δ (95% CI) −1.42 (−1.99–−0.85) −5.68 (−6.60–−4.77) −9.02 (−10.14–−7.91)
Placebo Mean ± SD 30.4 ± 8.1 29.2 ± 8.6 25.1 ± 10.4 22.8 ± 11.3
Δ (95% CI) −1.10 (−1.67–−0.52) −5.53 (−6.43–−4.64) −8.30 (−9.40–−7.20)
Group difference −0.32 (−1.13–0.49) −0.15 (−1.43–1.13) −0.73 (−2.29–0.84) N/A¶
ADAS-Cog 12 Placebo time trend (per week) 0.120 (0.109–0.132) N/A¶
Nilvadipine change in trend −0.002 (−0.019–0.014)
CDR-sb Placebo time trend (per week) 0.043 (0.040–0.047) N/A¶
Nilvadipine change in trend 0.0005 (−0.005–0.005)
Δ Change from baseline.
From F test for Visit × Arm interaction term. All models were controlled for baseline measurement and included country as a random effect and unstructured
correlation between time points.
ƗScores on the ADAS-Cog 12 range from 0 to 80, with higher scores indicating greater cognitive impairment [18].
ǂScores on the CDR-sb range from 0 to 18, with higher scores indicating worse functioning [19].
§Scores on the DAD range from 0 to 100, with higher scores indicating less impairment [20].
¶ After the nonsignificant outcome on the primary outcome ADAS-Cog 12, all other primary and secondary gated outcomes are not judged for significance, as defined
by the preplanned analysis.
Abbreviations: ADAS-Cog 12, Alzheimer’s Disease Assessment Scale Cognitive-12; CDR-sb, Clinical Dementia Rating Scale sum of boxes; DAD, Disability Assessment
for Dementia.
https://doi.org/10.1371/journal.pmed.1002660.t003
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groups in terms of antihypertensive use (J. Claassen & M.G.M. Olde Rikkert, personal commu-
nication, see S4 Text).
The overall safety and AE profile for nilvadipine was favourable in this older population.
There was no significant difference in the number of deaths, AEs, or SAEs that could be attrib-
uted to treatment. Blood pressure effects were modest, with only a median 5 mmHg drop in
systolic blood pressure from baseline to week 78 in the nilvadipine treated group.
The findings from the predefined subgroup analyses suggest differential effects of nilvadi-
pine in those at a milder disease stage, in APOE ε4 allele carriers, and in males. However, no
significance tests were conducted on these subgroups, and these findings will require further
investigation to determine if there are specific subgroups within the overall population that
respond either positively or negatively to nilvadipine treatment. For instance, consistent with
other anti-amyloid treatment trials suggesting that milder patients may respond better [23], in
these exploratory analyses, those with an SMMSE >20 appeared to decline at a slower rate
than those with an SMMSE <20. However, greater decline on the ADAS-Cog 12 in moderate-
stage patients on nilvadipine treatment should also be noted. Similarly, the gender and APOE
ε4 allele carrier results warrant further exploration, although the number of patients partici-
pating in the APOE study (64%) was fewer than the overall treatment population. Further
exploratory analyses, making use of the sub-study data, will look for correlation between
Fig 2. Estimated marginal means and 95% confidence intervals of the per-visit change from baseline in cognition
and functional performance, as measured by the primary and key secondary outcomes, respectively. ADAS/
ADAS-Cog 12, Alzheimer’s Disease Assessment Scale Cognitive-12; CDR/CDR-sb, Clinical Dementia Rating Scale
sum of boxes; DAD, Disability Assessment for Dementia.
https://doi.org/10.1371/journal.pmed.1002660.g002
Table 4. Safety end points.
Characteristics Nilvadipine
(N = 252)
Placebo
(N = 257)
Adverse Events
Total logged 1,129 1,030
Possibly, Probably, or Definitely related to IMP 223 178
Patients 206 (82%) 201 (78%)
Patients with Possibly, Probably, or Definitely related 142 (56%) 145 (56%)
Patients with Dizziness 30 (12%) 29 (11%)
Patients with Fall 40 (16%) 38 (15%)
Patients with Fracture 16 (6%) 9 (4%)
Patients with Peripheral edema 15 (6%) 3 (1%)
Patients with Syncope 12 (5%) 10 (4%)
Serious Adverse Events
Total logged 146 101
Possibly, Probably, or Definitely related to IMP 17 19
Patients 50 (20%) 42 (16%)
Patients with Possibly, Probably, or Definitely related 7 (3%) 9 (4%)
MortalityƗ 3 (1.2%) 4 (1.6%)
ƗThree further individuals died at or after week 82 of the study (all in the placebo group).
Note that patients are counted if they had one or more events of the type listed.
Abbreviations: CDR, CDR-sb (Clinical Dementia Rating sum of boxes); DAD, Disability Assessment for Dementia;
DBP, diastolic blood pressure; IMP, investigational medicinal product; mITT, modified intention-to-treat; SBP,
systolic blood pressure; SMMSE, Standardised Mini-Mental State Examination.
https://doi.org/10.1371/journal.pmed.1002660.t004
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biomarkers (in both blood and cerebrospinal fluid [CSF]), cerebral blood flow, and other
brain imaging data to better understand whether specific mechanisms, e.g., via a blood pres-
sure–lowering pathway or changes in Aβ or tau correlate with cognitive change.
The strengths of this investigator-driven clinical trial include the successful recruitment
and retention of participants and the conduct of the study to a high standard. There are, how-
ever, a number of issues related to the study design that could be considered for future trials of
this nature that are suggested by our main findings. Firstly, a single-dose strategy was used,
and it is possible that an insufficient dose was given to effect a treatment response. The side
effect profile for nilvadipine in this older, mild to moderate Alzheimer disease population was
favourable and the effect on blood pressure quite modest, so it would probably have been safe
to give a higher dose. While we predicted that any effect of nilvadipine on cognition would be
via an anti-amyloid rather than a blood pressure–lowering pathway, it is possible that a lack of
benefit in the overall population may have been contributed to by the modest blood pressure–
lowering effect of nilvadipine in this study. Secondly, the lack of biomarker confirmation of
the diagnosis of Alzheimer disease, which could mean that up to 20% of patients included in
the trial may not have had significant amyloid pathology [24], could be taken into account in
the design of future trials of this nature. A third issue to consider is the timing of the interven-
tion in the course of Alzheimer disease. Many anti-amyloid treatments have failed in popula-
tions with established mild to moderate Alzheimer disease, and it is a commonly held belief
that it may be too late to treat established dementia with amyloid-lowering drugs when there is
already associated significant neuronal damage [25]. Similarly, if cerebral hypoperfusion trig-
gers or accelerates the deposition of amyloid pathology, intervention with a drug that can
improve cerebral blood flow should occur at the earliest possible stage if it is to be effective as a
disease-modifying agent. The latter two limitations reflect the rapidly evolving evidence over
recent years since this study was designed, highlighting the ability and necessity of more
detailed phenotyping and a focus on earlier-stage intervention. Treatment at the prodromal
stage of the Alzheimer disease process might therefore be a more successful point at which to
intervene with nilvadipine.
Conclusions
This study of Nilvadipine at a dose of 8 mg found no overall effect on slowing the rate of cogni-
tive decline in a population spanning mild to moderate Alzheimer disease.
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